Diaceutics (GB:DXRX)
LSE:DXRX
Want to see GB:DXRX full AI Analyst Report?
Top Page
Diaceutics
(LSE:DXRX)
Select Model
Select Model
Rating:59Neutral
Price Target:
148.00 p
▼(-8.36% Downside)
Action:Reiterated
Date:05/29/26
The score is driven mainly by solid underlying financial position and improving 2025 financial performance, but is pulled down by very weak technicals (price below key moving averages with negative momentum) and limited valuation support due to a negative P/E and no dividend yield.
Positive Factors
Conservative balance sheet
Very low leverage and sizable equity provide durable financial flexibility: supports multi-period commercialization programs, cushions revenue volatility, and enables opportunistic investment or M&A without immediate refinancing pressure, improving resilience over 2-6 months.
Negative Factors
Operating profitability still fragile
Although net profit and EBITDA improved, operating profit stayed slightly negative and margins have swung year-to-year. This fragility limits ability to consistently fund growth from operations and raises execution risk as the company seeks sustained operating profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage and sizable equity provide durable financial flexibility: supports multi-period commercialization programs, cushions revenue volatility, and enables opportunistic investment or M&A without immediate refinancing pressure, improving resilience over 2-6 months.
Read all positive factors
Diaceutics (DXRX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£125.12M
Dividend YieldN/A
Average Volume (3M)79.63K
Price to Earnings (P/E)1274.5
Beta (1Y)0.54
Revenue Growth19.53%
EPS GrowthN/A
CountryUK
Employees184
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)<0.01
Shares Outstanding84,922,280
10 Day Avg. Volume58,068
30 Day Avg. Volume79,634
Financial Highlights & Ratios
PEG Ratio-11.04
Price to Book (P/B)2.67
Price to Sales (P/S)2.82
P/FCF Ratio75.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£216.00Price Target Upside33.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£46.32M
Diaceutics Business Overview & Revenue Model
Company Description
Diaceutics PLC, established in 2005 and headquartered in Belfast, UK, is a company dedicated to accelerating the commercialization of diagnostic solutions. It offers global pharmaceutical companies comprehensive data, advanced analytics, and imple...
How the Company Makes Money
Diaceutics makes money primarily by selling services and solutions to life-sciences customers (e.g., pharmaceutical companies) and, where applicable, diagnostics/healthcare stakeholders that are trying to increase the adoption and quality of bioma...
Diaceutics Earnings Call Summary
Earnings Call Date:Sep 17, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Sep 29, 2026
Earnings Call Sentiment Positive
The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.Positive Updates
Revenue Growth
Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.
Negative Updates
EBITDA Loss
EBITDA loss widened to negative GBP 1.3 million compared to negative GBP 200,000 in June 2023.
Read all updates
Q2-2024 Updates
Positive
Negative
Revenue Growth
Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.
Read all positive updates
Company Guidance
In the Q2 2024 earnings call for Diaceutics, CEO Ryan Keeling detailed significant advancements achieved in the first half of the year, particularly emphasizing the launch of their PMx solution. The company has expanded its lab network, notably integrating rare disease data and enhancing European data capabilities, all contributing to a robust and automated data pipeline. This automation, aided by AI, has streamlined data handling from extraction to customer delivery. The PMx solution, which emerged as a pivotal development, has transformed their approach by directly engaging physicians with patient data, boosting engagement and conversion rates. The financial health of the company is strong, with a 24% revenue increase to £12.3 million and a gross profit margin of 87%. Diaceutics aims to transition to a 70% subscription-led revenue model by 2025, with recurring revenues currently at 55%. The company also reported a record order book of £27.9 million, with plans to achieve profitability and free cash flow generation by 2025.Diaceutics Financial Statement Overview
Summary
Income Statement
64
Positive
Balance Sheet
86
Very Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.44M | 32.16M | 23.70M | 19.50M | 13.94M |
| Gross Profit | 26.12M | 28.27M | 19.71M | 14.04M | 10.57M |
| EBITDA | 6.08M | 2.77M | 2.36M | 3.61M | 2.35M |
| Net Income | 97.00K | -1.70M | -1.75M | 724.00K | 561.00K |
Balance Sheet | |||||
| Total Assets | 50.01M | 48.62M | 46.34M | 48.26M | 45.01M |
| Cash, Cash Equivalents and Short-Term Investments | 7.34M | 12.74M | 16.67M | 19.84M | 19.68M |
| Total Debt | 1.15M | 1.06M | 1.21M | 1.33M | 1.56M |
| Total Liabilities | 9.53M | 8.76M | 5.56M | 5.74M | 4.36M |
| Stockholders Equity | 40.48M | 39.86M | 40.79M | 42.51M | 40.65M |
Cash Flow | |||||
| Free Cash Flow | 1.43M | -3.98M | -3.54M | 278.00K | -5.03M |
| Operating Cash Flow | 1.50M | 651.00K | 1.31M | 5.15M | 570.00K |
| Investing Cash Flow | -6.45M | -4.03M | -4.21M | -4.87M | -5.60M |
| Financing Cash Flow | -333.00K | -64.00K | -239.00K | -132.00K | -270.00K |
Diaceutics Technical Analysis
Neutral
161.50
Price Trends
159.85
Negative
157.27
Negative
154.72
Negative
Market Momentum
-4.43
Negative
45.85
Neutral
79.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:DXRX, the sentiment is Neutral. The current price of 161.5 is above the 20-day moving average (MA) of 145.68, above the 50-day MA of 159.85, and above the 200-day MA of 154.72, indicating a neutral trend. The MACD of -4.43 indicates Negative momentum. The RSI at 45.85 is Neutral, neither overbought nor oversold. The STOCH value of 79.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:DXRX.
Diaceutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £125.12M | 1,274.53 | -3.95% | ― | 19.53% | ― | |
59 Neutral | £111.46M | 56.62 | 3.01% | ― | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £20.87M | -2.06 | -153.92% | ― | 65.60% | 74.84% | |
48 Neutral | £19.89M | -0.49 | -104.73% | ― | 29.64% | 28.51% | |
40 Underperform | £7.08M | -0.17 | -316.67% | ― | 72.17% | 79.03% | |
39 Underperform | £8.30M | -0.33 | 425.97% | ― | ― | ― |
* Healthcare Sector Average
GB:DXRX
Diaceutics
148.00
33.00
28.70%
GB:CLBX
ANGLE plc
1.75
-5.75
-76.67%
GB:EKF
EKF Diagnostics Holdings
25.90
-0.55
-2.08%
GB:GDR
Genedrive
1.30
-0.16
-10.78%
GB:OBD
Oxford BioDynamics
0.17
-0.23
-57.69%
GB:RENX
Renalytix
1.90
-5.35
-73.79%
Diaceutics Corporate Events
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Diaceutics Posts 2025 Annual Report and Sets Date for 2026 AGM
Neutral
May 29, 2026
Diaceutics PLC has distributed its Annual Report for the year ended 31 December 2025 to shareholders, alongside the notice of its 2026 Annual General Meeting. The AGM is scheduled for 25 June 2026 in Belfast, with the report and meeting materials ...
Business Operations and StrategyFinancial Disclosures
Diaceutics Returns to Profit on Strong Revenue Growth and Record Order Book
Positive
May 26, 2026
Diaceutics reported a 20% rise in 2025 revenue to £38.4 million, 24% on a constant-currency basis, and returned to profitability with a £0.3 million pre-tax profit as Adjusted EBITDA jumped 80% to £7.6 million. Annual recurring reve...
Business Operations and StrategyFinancial Disclosures
Diaceutics Sets Date for 2025 Final Results and Investor Webinar
Positive
May 13, 2026
Diaceutics PLC, a technology and solutions firm for the pharma and biotech sectors, specialises in enabling the commercialisation of precision medicines. Through its DXRX – The Diagnostics Network platform, the company offers data analytics,...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics updates on executive share incentives and confirms total voting rights
Positive
May 5, 2026
Diaceutics has disclosed routine share purchases by three senior executives under its UK and Global Share Incentive Plans, with trustees acquiring small volumes of ordinary shares on behalf of the PDMRs and the company matching these purchases on ...
Business Operations and Strategy
Diaceutics Extends Belfast HQ Lease in Related Party Deal
Positive
Apr 16, 2026
Diaceutics has extended the lease on its Belfast headquarters with O’Connor McCann Limited, a related party due to the involvement of Non-Executive Chair Peter Keeling, in a move that secures its Northern Ireland base through August 2036. T...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics Issues Shares Under Employee Incentive Schemes in Latest Block Listing Update
Neutral
Apr 7, 2026
Diaceutics PLC has reported its latest block listing return for its UK and Global Share Incentive Plan, Employee Share Option Plan and Unapproved Share Option Plan, which cover employee and long-term incentive awards. During the period from 7 Octo...
Business Operations and Strategy
Diaceutics Executes Routine Management Share Purchases Under Incentive Plan With No Change to Share Capital
Neutral
Apr 1, 2026
Diaceutics PLC has reported routine share purchases under its UK and Global Share Incentive Plan, with trustees acquiring ordinary shares on behalf of senior executives Susanne Munksted, Jordan Clark and Nick Roberts. Under the schemes, each emplo...
Business Operations and StrategyRegulatory Filings and Compliance
Diaceutics Maintains Share Count as Executives Receive Matched Equity Awards
Neutral
Mar 3, 2026
Diaceutics PLC reported that trustees of its 2020 Employee Benefit Trust purchased small tranches of ordinary shares on behalf of senior executives under the company’s UK and Global Share Incentive Plans. These employee purchases, including ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.